Muscle Dysfunction in Patients With Chronic Obstructive Lung Disease (COPD): the Role of Sympathetic Activation
|ClinicalTrials.gov Identifier: NCT01750489|
Recruitment Status : Completed
First Posted : December 17, 2012
Last Update Posted : May 12, 2014
The objective of the project is to better understand the causes of exercise limitation, dyspnea and neurohumoral activation in patients with COPD. In particular, the investigators aim to explore the mutual interaction of neurohumoral activation and exercise limitation thereby focussing on differential effects of the peripheral muscle and the diaphragm.
Eventually the findings might influence treatment modalities. If sympathetic activation contributes to exercise limitation then drugs influencing the autonomic nervous system would be a reasonable therapeutic concept. If a reduction of sympathetic activity due to an alteration of the ergoreflex can be achieved by non-invasive ventilation this would help to improve dyspnea and exercise capacity.
|Condition or disease||Intervention/treatment||Phase|
|Chronic Obstructive Pulmonary Disease||Device: non-invasive ventilation (NIV)||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Skeletal and Respiratory Muscle Dysfunction in Patients With COPD: the Role of Sympathetic Activation|
|Study Start Date :||August 2011|
|Actual Primary Completion Date :||November 2012|
|No Intervention: COPD|
Experimental: COPD with non-invasive ventilation (NIV)
Starting non-invasive ventilation with the patient's own device during registration of MSNA.
Device: non-invasive ventilation (NIV)
|No Intervention: Healthy control subjects|
- muscle sympathetic nerve activity (MSNA) [ Time Frame: 90 minutes ]In a 90 minute microneurographic measurement muscle sympathetic nerve activity is assessed.
- Arterial stiffness [ Time Frame: 90 min ]
- VE/VCO2 [ Time Frame: During 8-15 minutes bicycle exercise ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01750489
|Goettingen, Germany, 37075|
|Principal Investigator:||Stefan Andreas, Professor||Universitaetsmedizin Goettingen|